Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer

Endocrine therapies for prostate cancer inhibit the androgen receptor (AR) transcription factor. In most cases, AR activity resumes during therapy and drives progression to castration-resistant prostate cancer (CRPC). However, therapy can also promote lineage plasticity and select for AR-independent...

Descripción completa

Detalles Bibliográficos
Autores principales: Che, Meixia, Chaturvedi, Aashi, Munro, Sarah A., Pitzen, Samuel P., Ling, Alex, Zhang, Weijie, Mentzer, Josh, Ku, Sheng-Yu, Puca, Loredana, Zhu, Yanyun, Bergman, Andries M., Severson, Tesa M., Forster, Colleen, Liu, Yuzhen, Hildebrand, Jacob, Daniel, Mark, Wang, Ting-You, Selth, Luke A., Hickey, Theresa, Zoubeidi, Amina, Gleave, Martin, Bareja, Rohan, Sboner, Andrea, Tilley, Wayne, Carroll, Jason S., Tan, Winston, Kohli, Manish, Yang, Rendong, Hsieh, Andrew C., Murugan, Paari, Zwart, Wilbert, Beltran, Himisha, Huang, R. Stephanie, Dehm, Scott M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568894/
https://www.ncbi.nlm.nih.gov/pubmed/34737261
http://dx.doi.org/10.1038/s41467-021-26612-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568894/
https://www.ncbi.nlm.nih.gov/pubmed/34737261
http://dx.doi.org/10.1038/s41467-021-26612-1

Ejemplares similares